Muhammad Usman Ghani, Maria Mehboob, Asma Khan, Muhammad Imran.
Efficacy of Intravitreal Bevacizumab for the Treatment of Zone I Type 1 Retinopathy of Prematurity.
Pak J Med Health Sci Jan ;12(2):713-5.

Aim: To determine the efficacy of intravitreal bevacizumab in treatment of type retinopathy of prematurity in zone I. Study Design: Prospective study Location and Duration: in Opthalmology department of Nishtar hospital Multan, Bahawal Victoria Hospital, Bahawalpur, and Mayo Hospital Lahore. from January 2015 to January 2018. Methods: One hundred and eight eyes of 54 patients having Zone I ROP (retinopathy) were included in our study. Three patients died during the follow up period. One hundred and two eyes completed the follow up period. Sample size was calculated from thereference study performed by Reza Karkhaneh etal 11. Sample was collected using non probability consecutive sampling technique. The outcome variable assessed during the study was regression of retinopathy of prematurity after neovascularization. Mean gestational age, mean birth weight, mean PMA at first injection, percent of patients cured at 90w of postmenstrual age, percent of patients requiring reinjection, mean time of recurrence, no. of patients developing the advanced disease and mean time of the surgery were the variables measured and statistically analyzed thereafter. Statistical analysis was performed using computer SPSS ver 23. Results: Full regression of retinopathy of was observed in 85 (83.3%) eyes at ninety weeks of postmenstrual age, after one Intravitreal Bevacizumab injection. Re-injection was required in 17 (16.7%) eyes due to recurring and persistent neovascularization. There was recurrence at a mean of 5.76+-2.05 weeks. Re-injection improved the condition in eight more eyes. Conclusion: It can be concluded that int ravitreal bevacizumab is effective in the treatment of zone I retinopathy of prematurity.

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com